Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Prostate Cancer, Early Chemotherapy

Christopher Sweeney

MD

🏢South Australian Immunogenomics Cancer Institute🌐Australia

Professor of Medicine

65
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Christopher Sweeney led the CHAARTED trial demonstrating that early docetaxel chemotherapy with androgen deprivation therapy significantly improves overall survival in metastatic hormone-sensitive prostate cancer, transforming treatment approaches for this disease. His subsequent work on genomic classifiers to identify patients most likely to benefit from intensified therapy is personalizing treatment decision-making.

Share:

🧪Research Fields 研究领域

prostate cancer
CHAARTED trial
docetaxel mHSPC
genomic classifiers
bipolar androgen therapy

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-02-01 | All information from publicly available academic sources

关注 Christopher Sweeney 的研究动态

Follow Christopher Sweeney's research updates

留下邮箱,当我们发布与 Christopher Sweeney(South Australian Immunogenomics Cancer Institute)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment